\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\-\\ bp\\:\\ 104\\/69\\ pulse\\:\\ 135\\ bpm\\ respiratory\\ rate\\:\\ 36\\ breaths\\/min\\ spo2\\:\\ 99\\%\\ on\\ room\\ air\ \(0\)\
\-\ constitutional\\:\\ she\\ appears\\ well\\-developed\\ and\\ well\\-nourished\\.\\ she\\ is\\ active\\.\ \(0\)\
\-\ nose\\:\\ firm\\ mass\\ on\\ the\\ left\\ nasal\\ ala\\,\\ with\\ obstruction\\ of\\ the\\ left\\ nasal\\ airway\\.\\ mass\\ measures\\ 1\\-2\\ cm\\ and\\ extends\\ toward\\ cheek\\.\\ no\\ fluctuance\\.\\ no\\ changes\\ in\\ overlying\\ skin\\.no\\ mucosal\\ edema\\,\\ rhinorrhea\\,\\ nasal\\ discharge\\ or\\ congestion\\.\\ no\\ foreign\\ body\\ in\\ the\\ right\\ nostril\\.\\ no\\ foreign\\ body\\ in\\ the\\ left\\ nostril\\.\ \(0\)\
\-\ she\\ has\\ no\\ cervical\\ adenopathy\\.\ \(0\)\
\-\ patient\\ was\\ given\\ chemotherapy\\,\\ radiation\\,\\ and\\ had\\ surgical\\ excision\\ of\\ mass\\.\ \(0\)\
\-\ solid\\ left\\ nasal\\ mass\\ which\\ enhances\\.\\ would\\ favor\\ a\\ solid\\ neoplasm\\ such\\ as\ \(0\)\
\-\ rhabdomyosarcoma\\.\ \(6\)\
\-\ alveolar\\ rhabdomyosarcoma\ \(1\)\
\-\ vascular\\ anomaly\\ \\(hemangioma\\)\\ vs\\ benign\\ fibroma\\ vs\\ rhabdomyosarcoma\\ vs\\ dermoid\ \(0\)\
\-\ 8\\ month\\ old\\ who\\ was\\ noted\\ to\\ have\\ a\\ bump\\ on\\ her\\ left\\ nostril\\ about\\ 3\\ months\\ ago\\.\\ the\\ mass\\ has\\ grown\\ fairly\\ quickly\\ otherwise\\.\\ she\\ has\\ some\\ mild\\ nasal\\ congestion\\ and\\ mouth\\ breathing\\ over\\ the\\ last\\ few\\ weeks\\.\\ she\\ is\\ eating\\ and\\ gaining\\ weight\\ well\\.\\ she\\ was\\ born\\ at\\ 37\\ weeks\\.\\ she\\ had\\ no\\ complications\\ during\\ pregnancy\\ or\\ birth\\.\\ she\\ is\\ meeting\\ all\\ milestones\\.\\ she\\ passed\\ her\\ newborn\\ hearing\\ screen\\.\\ ros\\ negative\\.\ \(0\)\
\-\ rhabdomyosarcoma\\â\\€\\™s\\ are\\ malignant\\ tumors\\ of\\ mesenchymal\\ origin\\ that\\ are\\ from\\ precursor\\ skeletal\\ muscle\\ cells\\.\\ these\\ tumors\\ can\\ arise\\ in\\ many\\ different\\ locations\\ and\\ clinically\\ present\\ as\\ different\\ tissue\\ types\\,\\ including\\ fat\\,\\ muscle\\ and\\ soft\\ tissue\\.\\ unfortunately\\,\\ the\\ prognosis\\ of\\ these\\ tumors\\ is\\ extremely\\ poor\\,\\ especially\\ with\\ metastasis\\.\\ fortunately\\ these\\ tumors\\ are\\ relatively\\ rare\\ and\\ the\\ prognosis\\ has\\ been\\ steadily\\ improving\\ for\\ non\\-metastatic\\ disease\\.\\ there\\ are\\ 3\\ different\\ histological\\ subtypes\\ of\\ this\\ tumor\\;\\ alveolar\\,\\ embryonal\\,\\ and\\ pleomorphic\\/anaplastic\\.\\ \ \(0\)\
\-\ rhabdomyosarcoma\\â\\€\\™s\\ are\\ the\\ most\\ common\\ type\\ of\\ soft\\ tissue\\ tumors\\ in\\ the\\ pediatric\\ population\\,\\ but\\ are\\ still\\ rare\\ tumors\\ in\\ general\\.\\ they\\ have\\ a\\ 3\\ to\\ 4\\ percent\\ prevalence\\ rate\\ for\\ pediatric\\ patients\\ overall\\,\\ with\\ two\\-thirds\\ of\\ cases\\ diagnosed\\ under\\ the\\ age\\ of\\ six\\ \\[1\\]\\.\\ there\\ is\\ a\\ race\\ predilection\\ with\\ higher\\ incidence\\ in\\ blacks\\ than\\ whites\\ and\\ lower\\ incidence\\ in\\ asians\\ than\\ whites\\.\\ there\\ also\\ seems\\ to\\ be\\ male\\ predominance\\ with\\ a\\ male\\ to\\ female\\ ratio\\ that\\ is\\ 1\\.3\\-1\\.5\\.\\ these\\ tumors\\ can\\ be\\ seen\\ in\\ many\\ locations\\ throughout\\ the\\ body\\,\\ however\\ the\\ most\\ common\\ locations\\ are\\ the\\ head\\ and\\ neck\\ region\\ \\(36\\%\\)\\,\\ genitourinary\\ tract\\ \\(23\\%\\)\\,\\ extremities\\ \\(19\\%\\)\\ and\\ others\\ \\(22\\%\\)\\ \\[2\\]\\.\ \(0\)\
\-\ of\\ the\\ 3\\ different\\ histological\\ subtypes\\,\\ the\\ embryonal\\ is\\ the\\ most\\ common\\ \\(70\\-80\\%\\)\\,\\ followed\\ by\\ alveolar\\ \\(15\\-20\\%\\)\\,\\ and\\ pleomorphic\\/anaplastic\\ subtypes\\ are\\ extremely\\ rare\\ \\[3\\]\\.\\ in\\ addition\\ to\\ the\\ histological\\ features\\ of\\ the\\ tumor\\,\\ the\\ genetic\\ and\\ molecular\\ features\\ are\\ analyzed\\ for\\ further\\ management\\ and\\ prognostic\\ value\\.\\ each\\ histological\\ subtype\\ has\\ its\\ own\\ molecular\\ component\\.\\ for\\ the\\ embryonal\\ subtype\\,\\ the\\ cells\\ can\\ by\\ analyzed\\ for\\ a\\ myod1\\ mutation\\ \\(a\\ poorer\\ outcome\\)\\.\\ the\\ alveolar\\ subtype\\ can\\ have\\ a\\ translocation\\ between\\ the\\ foxo1\\ and\\ pax3\\ or\\ pax7\\ genes\\.\\ studies\\ have\\ shown\\ that\\ a\\ positive\\ foxo1\\ translocation\\ could\\ have\\ a\\ worse\\ prognosis\\ \\[4\\]\\.\\ in\\ addition\\ to\\ molecular\\ analysis\\,\\ prognosis\\ is\\ determined\\ by\\ the\\ typical\\ factors\\ of\\ most\\ neoplasms\\,\\ stage\\ and\\ grade\\.\\ however\\,\\ with\\ rhabdomyosarcoma\\â\\€\\™s\\ there\\ are\\ some\\ additional\\ prognostic\\ factors\\ that\\ are\\ looked\\ at\\.\\ histologic\\ subtype\\ is\\ a\\ factor\\ that\\ is\\ used\\ for\\ prognosis\\.\\ pleomorphic\\ subtypes\\ have\\ the\\ best\\ prognosis\\ of\\ the\\ 3\\ major\\ subtypes\\ \\(75\\%\\ 5\\-year\\ survival\\ rate\\)\\ followed\\ by\\ embryonal\\ \\(66\\%\\ 5\\-year\\ survival\\ rate\\)\\ and\\ then\\ alveolar\\ \\(54\\%\\ 5\\-year\\ survival\\ rate\\)\\.\\ \\ \ \(0\)\
\-\ a\\ high\\ degree\\ of\\ suspension\\ is\\ required\\ to\\ make\\ the\\ diagnosis\\ for\\ a\\ rhabdomyosarcoma\\.\\ majority\\ cases\\ sporadic\\,\\ but\\ there\\ are\\ some\\ associations\\ with\\ genetic\\ syndromes\\,\\ such\\ as\\,\\ li\\-fraumeni\\,\\ beckwith\\-wiedemann\\,\\ and\\ costello\\ syndromes\\ \\[3\\]\\.\\ signs\\ of\\ rhabdomyosarcoma\\ can\\ include\\,\\ lump\\ or\\ swelling\\ that\\ doesn\\â\\€\\™t\\ go\\ away\\ or\\ grows\\ rapidly\\,\\ bulging\\ of\\ the\\ eye\\,\\ headache\\,\\ and\\ epistaxis\\.\\ since\\ the\\ presentation\\ can\\ be\\ non\\-specific\\,\\ further\\ investigation\\ includes\\,\\ doppler\\ ultrasound\\ for\\ assessment\\ of\\ flow\\,\\ biopsy\\ of\\ the\\ mass\\,\\ and\\ mri\\ is\\ preferable\\ in\\ head\\ and\\ neck\\ tumors\\,\\ paraspinal\\ tumors\\,\\ limb\\ and\\ genitourinary\\ primaries\\ and\\ ct\\ is\\ recommended\\ for\\ tumors\\ in\\ the\\ chest\\ and\\ abdomen\\.\\ after\\ appropriate\\ work\\ up\\ and\\ diagnosis\\,\\ proper\\ management\\ can\\ be\\ initiated\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\	ries\\ lag\\,\\ harkins\\ d\\,\\ krapcho\\ m\\,\\ et\\ al\\.\\ seer\\ cancer\\ statistics\\ review\\ 1975\\-2011\\,\\ national\\ cancer\\ institute\\.\\ bethesda\\,\\ md\\.\\ https\\:\\/\\/seer\\.cancer\\.gov\\/archive\\/csr\\/1975\\_2011\ \(0\)\
\-\ 2\\.\\	sultan\\ i\\,\\ qaddoumi\\ i\\,\\ yaser\\ s\\,\\ et\\ al\\.\\ comparing\\ adult\\ and\\ pediatric\\ rhabdomyosarcoma\\ in\\ the\\ surveillance\\,\\ epidemiology\\ and\\ end\\ results\\ program\\,\\ 1973\\ to\\ 2005\\:\\ an\\ analysis\\ of\\ 2\\,600\\ patients\\.\\ j\\ clin\\ oncol\\.\\ 2009\\;27\\:3391\\â\\€\\“7\\.\ \(0\)\
\-\ 3\\.\\	panda\\ sp\\,\\ chinnaswamy\\ g\\,\\ vora\\ t\\,\\ et\\ al\\.\\ diagnosis\\ and\\ management\\ of\\ rhabdomyosarcoma\\ in\\ children\\ and\\ adolescents\\:\\ icmr\\ consensus\\ document\\.\\ indian\\ j\\ ped\\.\\ may\\ 2017\\:\\ 84\\:\\ 393\\-402\\.\\ \ \(0\)\
\-\ 4\\.\\	skapek\\ sx\\,\\ anderson\\ j\\,\\ barr\\ fg\\,\\ et\\ al\\.\\ pax\\-foxo1\\ fusion\\ status\\ drives\\ unfavorable\\ outcome\\ for\\ children\\ with\\ rhabdomyosarcoma\\:\\ a\\ children\\'s\\ oncology\\ group\\ report\\.\\ pediatr\\ blood\\ cancer\\.\\ 2013\\;60\\:1411\\â\\€\\“7\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.05538223835191026\ \(0\)\
\-\ tumors\\:\\ 0\\.0336095953682775\ \(0\)\
\-\ subtypes\\:\\ 0\\.030214638671429712\ \(0\)\
\-\ alveolar\\:\\ 0\\.02671176103278634\ \(0\)\
\-\ prognosis\\:\\ 0\\.02546603867540571\ \(0\)\
\-\ nostril\\:\\ 0\\.02424158995381693\ \(0\)\
\-\ embryonal\\:\\ 0\\.02417171093714377\ \(0\)\
\-\ subtype\\:\\ 0\\.02417171093714377\ \(0\)\
\-\ \\]\\:\\ 0\\.023412109958705834\ \(0\)\
\-\ \\[\\:\\ 0\\.02334455286532412\ \(0\)\
\-\ she\\:\\ 0\\.022606361542500054\ \(0\)\
\-\ histological\\:\\ 0\\.02227857952879589\ \(0\)\
\-\ nasal\\:\\ 0\\.022149481388983906\ \(0\)\
\-\ \\%\\:\\ 0\\.020872471553361336\ \(0\)\
\-\ molecular\\:\\ 0\\.020459476432374196\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.019635295496874223\ \(0\)\
\-\ pleomorphic\\/anaplastic\\:\\ 0\\.018461818688935077\ \(0\)\
\-\ foxo1\\:\\ 0\\.018461818688935077\ \(0\)\
\-\ different\\:\\ 0\\.017719585111187125\ \(0\)\
\-\ rate\\:\\ 0\\.017438332410868288\ \(0\)\
\-\ \\,\\:\\ 0\\.015874098082689102\ \(0\)\
\-\ locations\\:\\ 0\\.01566558228526933\ \(0\)\
\-\ analyzed\\:\\ 0\\.015558584424809651\ \(0\)\
\-\ translocation\\:\\ 0\\.015558584424809651\ \(0\)\
\-\ \\:\\:\\ 0\\.015385939903537848\ \(0\)\
\-\ al\\:\\ 0\\.015173032766811678\ \(0\)\
\-\ 3\\:\\ 0\\.014666836321409192\ \(0\)\
\-\ et\\:\\ 0\\.014648789236114271\ \(0\)\
\-\ are\\:\\ 0\\.014637158607701803\ \(0\)\
\-\ survival\\:\\ 0\\.014391869903777714\ \(0\)\
\-\ can\\:\\ 0\\.014206865410768049\ \(0\)\
\-\ whites\\:\\ 0\\.013639650954916132\ \(0\)\
\-\ pediatric\\:\\ 0\\.012926821125154184\ \(0\)\
\-\ j\\:\\ 0\\.01212468492051907\ \(0\)\
\-\ genitourinary\\:\\ 0\\.011988431352059022\ \(0\)\
\-\ prognostic\\:\\ 0\\.011988431352059022\ \(0\)\
\-\ have\\:\\ 0\\.01162578897402152\ \(0\)\
\-\ children\\:\\ 0\\.01159650610857562\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.010697494197467879\ \(0\)\
\-\ outcome\\:\\ 0\\.010684704413114535\ \(0\)\
\-\ vs\\:\\ 0\\.010569047027437061\ \(0\)\
\-\ rare\\:\\ 0\\.010424136749759045\ \(0\)\
\-\ s\\:\\ 0\\.010264995464354292\ \(0\)\
\-\ syndromes\\:\\ 0\\.01022762888218256\ \(0\)\
\-\ extremely\\:\\ 0\\.010186962733790723\ \(0\)\
\-\ management\\:\\ 0\\.010129418146981073\ \(0\)\
\-\ genetic\\:\\ 0\\.009785096748848096\ \(0\)\
\-\ congestion\\:\\ 0\\.009752115896558798\ \(0\)\
\-\ these\\:\\ 0\\.009314532741184671\ \(0\)\
\-\ that\\:\\ 0\\.009273177352202032\ \(0\)\
\-\ skin\\.no\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ non\\-metastatic\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 1\\.3\\-1\\.5\\.\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ myod1\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ pax3\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ pax7\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ costello\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ ries\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ harkins\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ krapcho\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ seer\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 1975\\-2011\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ \\/\\/seer\\.cancer\\.gov\\/archive\\/csr\\/1975\\_2011\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ sultan\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ qaddoumi\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ yaser\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 2\\,600\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 27\\:3391\\â\\€\\“7\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ chinnaswamy\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ vora\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ icmr\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 393\\-402\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ skapek\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ barr\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ fg\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ pax\\-foxo1\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ 60\\:1411\\â\\€\\“7\\:\\ 0\\.009230909344467539\ \(0\)\
\-\ analysis\\:\\ 0\\.009109131529449036\ \(0\)\
\-\ 36\\:\\ 0\\.008969463729451817\ \(0\)\
\-\ cancer\\:\\ 0\\.00882460292470607\ \(0\)\
\-\ foreign\\:\\ 0\\.008817483220897187\ \(0\)\
\-\ body\\:\\ 0\\.008718105903735344\ \(0\)\
\-\ vitals\\-\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ 104\\/69\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ breaths\\/min\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ fluctuance\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ li\\-fraumeni\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ panda\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ drives\\:\\ 0\\.008505100778436182\ \(0\)\
\-\ has\\:\\ 0\\.008401570526148053\ \(0\)\
\-\ \\(\\:\\ 0\\.008320396846787922\ \(0\)\
\-\ t\\:\\ 0\\.008284201088177647\ \(0\)\
\-\ most\\:\\ 0\\.008263183839698748\ \(0\)\
\-\ \\)\\:\\ 0\\.008218758757326026\ \(0\)\
\-\ incidence\\:\\ 0\\.008204562563383429\ \(0\)\
\-\ some\\:\\ 0\\.008151607080209714\ \(0\)\
\-\ asians\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ suspension\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ beckwith\\-wiedemann\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ statistics\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ bethesda\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ ped\\:\\ 0\\.008080529984605643\ \(0\)\
\-\ factors\\:\\ 0\\.008039339647216594\ \(0\)\
\-\ gaining\\:\\ 0\\.007779292212404826\ \(0\)\
\-\ 1973\\:\\ 0\\.007779292212404826\ \(0\)\
\-\ is\\:\\ 0\\.007654220019896788\ \(0\)\
\-\ for\\:\\ 0\\.007634640299923719\ \(0\)\
\-\ addition\\:\\ 0\\.007586516383405839\ \(0\)\
\-\ features\\:\\ 0\\.007551900044241001\ \(0\)\
\-\ 135\\:\\ 0\\.007545634043489423\ \(0\)\
\-\ poorer\\:\\ 0\\.007545634043489423\ \(0\)\
\-\ doesn\\:\\ 0\\.007545634043489423\ \(0\)\
\-\ preferable\\:\\ 0\\.007545634043489423\ \(0\)\
\-\ primaries\\:\\ 0\\.007545634043489423\ \(0\)\
\-\ mass\\:\\ 0\\.007466770724277892\ \(0\)\
\-\ i\\:\\ 0\\.00739751768634243\ \(0\)\
\-\ many\\:\\ 0\\.0073554209757223515\ \(0\)\
\-\ ala\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ blacks\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ 70\\-80\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ institute\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ sp\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ unfavorable\\:\\ 0\\.007354721418574286\ \(0\)\
\-\ precursor\\:\\ 0\\.007193307094147838\ \(0\)\
\-\ genes\\:\\ 0\\.007193307094147838\ \(0\)\
\-\ cells\\:\\ 0\\.007175804595078529\ \(0\)\
\-\ solid\\:\\ 0\\.007137898748704461\ \(0\)\
\-\ meeting\\:\\ 0\\.007053483646373469\ \(0\)\
\-\ steadily\\:\\ 0\\.007053483646373469\ \(0\)\
\-\ anderson\\:\\ 0\\.007053483646373469\ \(0\)\
\-\ common\\:\\ 0\\.007024923178920619\ \(0\)\
\-\ fortunately\\:\\ 0\\.0069301506247437476\ \(0\)\
\-\ associations\\:\\ 0\\.0069301506247437476\ \(0\)\
\-\ oncol\\:\\ 0\\.0069301506247437476\ \(0\)\
\-\ indian\\:\\ 0\\.0069301506247437476\ \(0\)\
\-\ race\\:\\ 0\\.006819825477458066\ \(0\)\
\-\ 15\\-20\\:\\ 0\\.006819825477458066\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.006720024242060868\ \(0\)\
\-\ milestones\\:\\ 0\\.006720024242060868\ \(0\)\
\-\ looked\\:\\ 0\\.006720024242060868\ \(0\)\
\-\ lag\\:\\ 0\\.006720024242060868\ \(0\)\
\-\ comparing\\:\\ 0\\.006720024242060868\ \(0\)\
\-\ there\\:\\ 0\\.006658196630706747\ \(0\)\
\-\ two\\-thirds\\:\\ 0\\.00662891285254293\ \(0\)\
\-\ grows\\:\\ 0\\.00662891285254293\ \(0\)\
\-\ sx\\:\\ 0\\.00662891285254293\ \(0\)\
\-\ in\\:\\ 0\\.0066188046618888205\ \(0\)\
\-\ well\\-nourished\\:\\ 0\\.0065450984989580754\ \(0\)\
\-\ grown\\:\\ 0\\.0065450984989580754\ \(0\)\
\-\ consensus\\:\\ 0\\.0065450984989580754\ \(0\)\
\-\ epistaxis\\:\\ 0\\.0064674985281164814\ \(0\)\
\-\ epidemiology\\:\\ 0\\.0064674985281164814\ \(0\)\
\-\ pediatr\\:\\ 0\\.0064674985281164814\ \(0\)\
\-\ muscle\\:\\ 0\\.0064278853056049115\ \(0\)\
\-\ program\\:\\ 0\\.006395254683627527\ \(0\)\
\-\ document\\:\\ 0\\.006395254683627527\ \(0\)\
\-\ 2017\\:\\ 0\\.006395254683627527\ \(0\)\
\-\ tissue\\:\\ 0\\.0063625796495893\ \(0\)\
\-\ \\;\\:\\ 0\\.0063625796495893\ \(0\)\
\-\ well\\-developed\\:\\ 0\\.006327675080342113\ \(0\)\
\-\ national\\:\\ 0\\.006327675080342113\ \(0\)\
\-\ adolescents\\:\\ 0\\.006327675080342113\ \(0\)\
\-\ diagnosis\\:\\ 0\\.006164039782556293\ \(0\)\
\-\ spo2\\:\\ 0\\.006147727167329905\ \(0\)\
\-\ favor\\:\\ 0\\.006147727167329905\ \(0\)\
\-\ bump\\:\\ 0\\.006147727167329905\ \(0\)\
\-\ cheek\\:\\ 0\\.006094016911426709\ \(0\)\
\-\ quickly\\:\\ 0\\.006042927734285943\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.006042927734285943\ \(0\)\
\-\ investigation\\:\\ 0\\.006042927734285943\ \(0\)\
\-\ followed\\:\\ 0\\.005999740044772297\ \(0\)\
\-\ ros\\:\\ 0\\.005994215676029511\ \(0\)\
\-\ improving\\:\\ 0\\.005994215676029511\ \(0\)\
\-\ cases\\:\\ 0\\.005961907568546875\ \(0\)\
\-\ by\\:\\ 0\\.005959668704690575\ \(0\)\
\-\ seems\\:\\ 0\\.0059476693277878\ \(0\)\
\-\ constitutional\\:\\ 0\\.005903104286511573\ \(0\)\
\-\ predilection\\:\\ 0\\.005903104286511573\ \(0\)\
\-\ a\\:\\ 0\\.005814028508335516\ \(0\)\
\-\ bpm\\:\\ 0\\.005779771264881853\ \(0\)\
\-\ sporadic\\:\\ 0\\.005779771264881853\ \(0\)\
\-\ own\\:\\ 0\\.0057416899620851254\ \(0\)\
\-\ mutation\\:\\ 0\\.005704945124586413\ \(0\)\
\-\ 2009\\:\\ 0\\.005704945124586413\ \(0\)\
\-\ oncology\\:\\ 0\\.005704945124586413\ \(0\)\
\-\ 2013\\:\\ 0\\.005704945124586413\ \(0\)\
\-\ further\\:\\ 0\\.005690982495916772\ \(0\)\
\-\ histologic\\:\\ 0\\.0056694461175961705\ \(0\)\
\-\ and\\:\\ 0\\.005654733164362883\ \(0\)\
\-\ 84\\:\\ 0\\.005635111224587804\ \(0\)\
\-\ 99\\:\\ 0\\.005601866514310756\ \(0\)\
\-\ predominance\\:\\ 0\\.005601866514310756\ \(0\)\
\-\ such\\:\\ 0\\.005594414219561995\ \(0\)\
\-\ https\\:\\ 0\\.005569644882198972\ \(0\)\
\-\ surveillance\\:\\ 0\\.005569644882198972\ \(0\)\
\-\ be\\:\\ 0\\.005519399888351536\ \(0\)\
\-\ prevalence\\:\\ 0\\.005508031793169723\ \(0\)\
\-\ go\\:\\ 0\\.005508031793169723\ \(0\)\
\-\ proper\\:\\ 0\\.005508031793169723\ \(0\)\
\-\ initiated\\:\\ 0\\.005508031793169723\ \(0\)\
\-\ eating\\:\\ 0\\.005449843467353167\ \(0\)\
\-\ no\\:\\ 0\\.005405931836882526\ \(0\)\
\-\ passed\\:\\ 0\\.005394719139096181\ \(0\)\
\-\ bulging\\:\\ 0\\.005394719139096181\ \(0\)\
\-\ her\\:\\ 0\\.0053809668240522215\ \(0\)\
\-\ g\\:\\ 0\\.005292479903950718\ \(0\)\
\-\ others\\:\\ 0\\.005268407109998154\ \(0\)\
\-\ clin\\:\\ 0\\.005268407109998154\ \(0\)\
\-\ neck\\:\\ 0\\.005254959449253367\ \(0\)\
\-\ fairly\\:\\ 0\\.005244875323765633\ \(0\)\
\-\ or\\:\\ 0\\.005243574601904228\ \(0\)\
\-\ lump\\:\\ 0\\.0052218607617564436\ \(0\)\
\-\ screen\\:\\ 0\\.005199341175137634\ \(0\)\
\-\ away\\:\\ 0\\.005199341175137634\ \(0\)\
\-\ non\\-specific\\:\\ 0\\.005177295720480218\ \(0\)\
\-\ nose\\:\\ 0\\.005155704843828138\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.00513455017647995\ \(0\)\
\-\ unfortunately\\:\\ 0\\.00513455017647995\ \(0\)\
\-\ toward\\:\\ 0\\.005093481366895362\ \(0\)\
\-\ weeks\\:\\ 0\\.00507911572125895\ \(0\)\
\-\ head\\:\\ 0\\.005075604838898212\ \(0\)\
\-\ value\\:\\ 0\\.005073535612999348\ \(0\)\
\-\ limb\\:\\ 0\\.005053962698850497\ \(0\)\
\-\ mouth\\:\\ 0\\.005034748941082751\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.005034748941082751\ \(0\)\
\-\ left\\:\\ 0\\.005005786750119973\ \(0\)\
\-\ 4\\:\\ 0\\.004986328597233603\ \(0\)\
\-\ however\\:\\ 0\\.004982969749941509\ \(0\)\
\-\ airway\\:\\ 0\\.004979136558555058\ \(0\)\
\-\ fibroma\\:\\ 0\\.004979136558555058\ \(0\)\
\-\ ratio\\:\\ 0\\.0049612366283358945\ \(0\)\
\-\ rapidly\\:\\ 0\\.0049612366283358945\ \(0\)\
\-\ newborn\\:\\ 0\\.004876057948279399\ \(0\)\
\-\ percent\\:\\ 0\\.004876057948279399\ \(0\)\
\-\ 2005\\:\\ 0\\.004828089847723071\ \(0\)\
\-\ breathing\\:\\ 0\\.004812576668890463\ \(0\)\
\-\ 66\\:\\ 0\\.004812576668890463\ \(0\)\
\-\ assessment\\:\\ 0\\.004812576668890463\ \(0\)\
\-\ make\\:\\ 0\\.004782223227138366\ \(0\)\
\-\ paraspinal\\:\\ 0\\.004782223227138366\ \(0\)\
\-\ the\\:\\ 0\\.004777200413842567\ \(0\)\
\-\ 54\\:\\ 0\\.00472403490132181\ \(0\)\
\-\ than\\:\\ 0\\.004689107549567066\ \(0\)\
\-\ born\\:\\ 0\\.004668910573064824\ \(0\)\
\-\ population\\:\\ 0\\.004668910573064824\ \(0\)\
\-\ determined\\:\\ 0\\.004668910573064824\ \(0\)\
\-\ group\\:\\ 0\\.004655571279057045\ \(0\)\
\-\ patients\\:\\ 0\\.004631569841604243\ \(0\)\
\-\ each\\:\\ 0\\.0046293919050199575\ \(0\)\
\-\ pulse\\:\\ 0\\.004616543640525912\ \(0\)\
\-\ mucosal\\:\\ 0\\.004616543640525912\ \(0\)\
\-\ m\\:\\ 0\\.004616543640525912\ \(0\)\
\-\ 75\\:\\ 0\\.00457891849997506\ \(0\)\
\-\ types\\:\\ 0\\.004566671337919362\ \(0\)\
\-\ factor\\:\\ 0\\.004566671337919362\ \(0\)\
\-\ neoplasms\\:\\ 0\\.004554565764724518\ \(0\)\
\-\ end\\:\\ 0\\.004542598543966798\ \(0\)\
\-\ 37\\:\\ 0\\.0044960521957250876\ \(0\)\
\-\ adult\\:\\ 0\\.0044847318647259085\ \(0\)\
\-\ d\\:\\ 0\\.004462451866351788\ \(0\)\
\-\ overall\\:\\ 0\\.004451487154448861\ \(0\)\
\-\ anomaly\\:\\ 0\\.004429896277796781\ \(0\)\
\-\ arise\\:\\ 0\\.004429896277796781\ \(0\)\
\-\ skeletal\\:\\ 0\\.004419265522337078\ \(0\)\
\-\ md\\:\\ 0\\.004419265522337078\ \(0\)\
\-\ hearing\\:\\ 0\\.0044087416104485935\ \(0\)\
\-\ six\\:\\ 0\\.004398322415837947\ \(0\)\
\-\ majority\\:\\ 0\\.004398322415837947\ \(0\)\
\-\ firm\\:\\ 0\\.004388005875059923\ \(0\)\
\-\ higher\\:\\ 0\\.004388005875059923\ \(0\)\
\-\ soft\\:\\ 0\\.004357961809410576\ \(0\)\
\-\ discharge\\:\\ 0\\.004337894858119992\ \(0\)\
\-\ doppler\\:\\ 0\\.00432815413281914\ \(0\)\
\-\ birth\\:\\ 0\\.004299464107491272\ \(0\)\
\-\ still\\:\\ 0\\.004262394026809685\ \(0\)\
\-\ 23\\:\\ 0\\.004253327992523701\ \(0\)\
\-\ enhances\\:\\ 0\\.0042265915506334755\ \(0\)\
\-\ appropriate\\:\\ 0\\.0042178289855334585\ \(0\)\
\-\ degree\\:\\ 0\\.004191972846695372\ \(0\)\
\-\ work\\:\\ 0\\.004191972846695372\ \(0\)\
\-\ major\\:\\ 0\\.004183494092525091\ \(0\)\
\-\ tumor\\:\\ 0\\.004172214244211123\ \(0\)\
\-\ 19\\:\\ 0\\.004125990681429683\ \(0\)\
\-\ origin\\:\\ 0\\.004102281281691714\ \(0\)\
\-\ component\\:\\ 0\\.004086768102859107\ \(0\)\
\-\ dermoid\\:\\ 0\\.0040790968566893964\ \(0\)\
\-\ as\\:\\ 0\\.004060452898096737\ \(0\)\
\-\ overlying\\:\\ 0\\.004048961815275739\ \(0\)\
\-\ few\\:\\ 0\\.004026916360618323\ \(0\)\
\-\ poor\\:\\ 0\\.004026916360618323\ \(0\)\
\-\ report\\:\\ 0\\.0040053254839662435\ \(0\)\
\-\ hemangioma\\:\\ 0\\.003998226335290454\ \(0\)\
\-\ 22\\:\\ 0\\.003991174992692188\ \(0\)\
\-\ fusion\\:\\ 0\\.003991174992692188\ \(0\)\
\-\ adenopathy\\:\\ 0\\.003984170816618055\ \(0\)\
\-\ tract\\:\\ 0\\.003963435081229386\ \(0\)\
\-\ worse\\:\\ 0\\.003963435081229386\ \(0\)\
\-\ clinically\\:\\ 0\\.0039231562531374525\ \(0\)\
\-\ under\\:\\ 0\\.0039100670774681\ \(0\)\
\-\ bp\\:\\ 0\\.0038843695812208565\ \(0\)\
\-\ extends\\:\\ 0\\.0038780425503769167\ \(0\)\
\-\ review\\:\\ 0\\.0038780425503769167\ \(0\)\
\-\ had\\:\\ 0\\.0038614655900328972\ \(0\)\
\-\ room\\:\\ 0\\.0038469684476061137\ \(0\)\
\-\ pregnancy\\:\\ 0\\.0038469684476061137\ \(0\)\
\-\ measures\\:\\ 0\\.003828757198693162\ \(0\)\
\-\ relatively\\:\\ 0\\.003828757198693162\ \(0\)\
\-\ last\\:\\ 0\\.003822756492191607\ \(0\)\
\-\ stage\\:\\ 0\\.003816789977935442\ \(0\)\
\-\ but\\:\\ 0\\.003816760839860812\ \(0\)\
\-\ general\\:\\ 0\\.0037702436296937307\ \(0\)\
\-\ best\\:\\ 0\\.003764568166375051\ \(0\)\
\-\ eye\\:\\ 0\\.0037533086985465044\ \(0\)\
\-\ references\\:\\ 0\\.003720238989593312\ \(0\)\
\-\ respiratory\\:\\ 0\\.0037148275025164087\ \(0\)\
\-\ recommended\\:\\ 0\\.0037094438381180647\ \(0\)\
\-\ especially\\:\\ 0\\.0036829330444172375\ \(0\)\
\-\ excision\\:\\ 0\\.00367251384980659\ \(0\)\
\-\ results\\:\\ 0\\.003612086292088636\ \(0\)\
\-\ includes\\:\\ 0\\.003607204602972603\ \(0\)\
\-\ shown\\:\\ 0\\.0035879022975392645\ \(0\)\
\-\ typical\\:\\ 0\\.0035879022975392645\ \(0\)\
\-\ additional\\:\\ 0\\.0035879022975392645\ \(0\)\
\-\ to\\:\\ 0\\.003577533892716116\ \(0\)\
\-\ complications\\:\\ 0\\.003545730675405296\ \(0\)\
\-\ 4\\.\\:\\ 0\\.003523015675812354\ \(0\)\
\-\ extremities\\:\\ 0\\.0035096194962731817\ \(0\)\
\-\ about\\:\\ 0\\.0034492748755018347\ \(0\)\
\-\ used\\:\\ 0\\.003432653567484777\ \(0\)\
\-\ active\\:\\ 0\\.0034162919780574667\ \(0\)\
\-\ grade\\:\\ 0\\.003408206065917247\ \(0\)\
\-\ its\\:\\ 0\\.003376472715660358\ \(0\)\
\-\ metastasis\\:\\ 0\\.0033494736401046355\ \(0\)\
\-\ throughout\\:\\ 0\\.0033494736401046355\ \(0\)\
\-\ 8\\:\\ 0\\.003345672835863192\ \(0\)\
\-\ studies\\:\\ 0\\.0033418857777792253\ \(0\)\
\-\ appears\\:\\ 0\\.0033306060950756534\ \(0\)\
\-\ ago\\:\\ 0\\.0033306060950756534\ \(0\)\
\-\ could\\:\\ 0\\.003301107794586966\ \(0\)\
\-\ diagnosed\\:\\ 0\\.00329025670868587\ \(0\)\
\-\ since\\:\\ 0\\.003286664525338447\ \(0\)\
\-\ cervical\\:\\ 0\\.003251404614232072\ \(0\)\
\-\ male\\:\\ 0\\.0032360325400784783\ \(0\)\
\-\ malignant\\:\\ 0\\.003234210132334347\ \(0\)\
\-\ including\\:\\ 0\\.0032308048596784546\ \(0\)\
\-\ they\\:\\ 0\\.0032240273575783315\ \(0\)\
\-\ required\\:\\ 0\\.0032206549861646745\ \(0\)\
\-\ otherwise\\:\\ 0\\.0032139426528024558\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0032072730734459326\ \(0\)\
\-\ weight\\:\\ 0\\.0032072730734459326\ \(0\)\
\-\ status\\:\\ 0\\.0031940600221797423\ \(0\)\
\-\ would\\:\\ 0\\.0031842585114367434\ \(0\)\
\-\ then\\:\\ 0\\.0031842585114367434\ \(0\)\
\-\ biopsy\\:\\ 0\\.0031745478970018437\ \(0\)\
\-\ obstruction\\:\\ 0\\.0031553927210360585\ \(0\)\
\-\ signs\\:\\ 0\\.0031490847476293767\ \(0\)\
\-\ was\\:\\ 0\\.0031045367189958747\ \(0\)\
\-\ benign\\:\\ 0\\.003088010855532148\ \(0\)\
\-\ presentation\\:\\ 0\\.0030820949052262647\ \(0\)\
\-\ headache\\:\\ 0\\.0030732831806971708\ \(0\)\
\-\ given\\:\\ 0\\.003067449625671563\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0030616483896761543\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0030472843726826477\ \(0\)\
\-\ air\\:\\ 0\\.003027500132515148\ \(0\)\
\-\ type\\:\\ 0\\.0030163604485307963\ \(0\)\
\-\ swelling\\:\\ 0\\.0029809537842734376\ \(0\)\
\-\ flow\\:\\ 0\\.002957124478385881\ \(0\)\
\-\ radiation\\:\\ 0\\.0029363887429972113\ \(0\)\
\-\ vascular\\:\\ 0\\.002933825411438426\ \(0\)\
\-\ positive\\:\\ 0\\.0029035451207163527\ \(0\)\
\-\ 2\\.\\:\\ 0\\.002845491247958386\ \(0\)\
\-\ between\\:\\ 0\\.0028361209803395224\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0027949624777985353\ \(0\)\
\-\ during\\:\\ 0\\.0027382295810720507\ \(0\)\
\-\ age\\:\\ 0\\.0027234663094704782\ \(0\)\
\-\ fat\\:\\ 0\\.0027213741600854804\ \(0\)\
\-\ month\\:\\ 0\\.002684413131728387\ \(0\)\
\-\ negative\\:\\ 0\\.0026723771323297115\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0026545786230432497\ \(0\)\
\-\ abdomen\\:\\ 0\\.002650664149629002\ \(0\)\
\-\ changes\\:\\ 0\\.002564448142654514\ \(0\)\
\-\ edema\\:\\ 0\\.002530809936577268\ \(0\)\
\-\ all\\:\\ 0\\.002530809936577268\ \(0\)\
\-\ region\\:\\ 0\\.0025273311279992803\ \(0\)\
\-\ include\\:\\ 0\\.0025101083644296198\ \(0\)\
\-\ high\\:\\ 0\\.0024487393309704877\ \(0\)\
\-\ months\\:\\ 0\\.0024439175860628977\ \(0\)\
\-\ blood\\:\\ 0\\.0024423152591720415\ \(0\)\
\-\ been\\:\\ 0\\.002434340198391614\ \(0\)\
\-\ at\\:\\ 0\\.002424634875040069\ \(0\)\
\-\ up\\:\\ 0\\.002406122671260967\ \(0\)\
\-\ cm\\:\\ 0\\.0023999540500701426\ \(0\)\
\-\ mild\\:\\ 0\\.0023562863391949082\ \(0\)\
\-\ who\\:\\ 0\\.002332951213760945\ \(0\)\
\-\ of\\:\\ 0\\.002317876665090869\ \(0\)\
\-\ over\\:\\ 0\\.00227815978025127\ \(0\)\
\-\ on\\:\\ 0\\.0022740031802055334\ \(0\)\
\-\ \\.\\:\\ 0\\.002230337346430132\ \(0\)\
\-\ chest\\:\\ 0\\.002141077486971224\ \(0\)\
\-\ 1\\:\\ 0\\.0021291375580729916\ \(0\)\
\-\ noted\\:\\ 0\\.002120859883196433\ \(0\)\
\-\ mri\\:\\ 0\\.0020557862355126914\ \(0\)\
\-\ well\\:\\ 0\\.002024168537139949\ \(0\)\
\-\ present\\:\\ 0\\.002020951574797572\ \(0\)\
\-\ lower\\:\\ 0\\.002012421015040694\ \(0\)\
\-\ \\'s\\:\\ 0\\.001972823684153974\ \(0\)\
\-\ may\\:\\ 0\\.0019626475066996064\ \(0\)\
\-\ 2\\:\\ 0\\.0019268109911105198\ \(0\)\
\-\ surgical\\:\\ 0\\.0018808604924098991\ \(0\)\
\-\ after\\:\\ 0\\.0018513101598002122\ \(0\)\
\-\ female\\:\\ 0\\.0018395395512542762\ \(0\)\
\-\ seen\\:\\ 0\\.0017681964555682622\ \(0\)\
\-\ also\\:\\ 0\\.0017639995745237188\ \(0\)\
\-\ which\\:\\ 0\\.0016703084683168052\ \(0\)\
\-\ disease\\:\\ 0\\.001462552399178748\ \(0\)\
\-\ from\\:\\ 0\\.0013261106944023168\ \(0\)\
\-\ ct\\:\\ 0\\.001251626862190621\ \(0\)\
\-\ an\\:\\ 0\\.0012373454076279895\ \(0\)\
\-\ this\\:\\ 0\\.0010064264013760556\ \(0\)\
\-\ with\\:\\ 0\\.0009801396949938408\ \(0\)\
\-\ right\\:\\ 0\\.0009441169728904888\ \(0\)\
\-\ old\\:\\ 0\\.0009161618815311567\ \(0\)\
\-\ patient\\:\\ 0\\.0008969549014831289\ \(0\)\
